4,5-dimethyl-1H-indazol-3-amine | 943247-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 4,5-dimethyl-1H-indazol-3-amine
• CAS: 943247-71-0
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: NZIYJBQKRFIHTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] FUSED RING COMPOUNDS<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS
  申请人：GENENTECH INC

  公开号：WO2020035031A1

  公开（公告）日：2020-02-20

  Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.

  提供的是公式(I)、公式(II)或公式(III)的融合环化合物，具体细节如下，这些化合物用于抑制Ras蛋白，以及包含这些化合物的组合物和通过其给药的治疗方法。
• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE RAS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018068017A1

  公开（公告）日：2018-04-12

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1, n2and '--" are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also disclosed.

  提供了具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、立体异构体或前药，其中A、B、R"、Q、W、X、Y、Z、n1、n2和'--'的定义如本文所述。还公开了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] BENZOTHIOPHENE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS À BASE DE BENZOTHIOPHÈNE ET DE BENZOTHIAZOLE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140599A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）或其药用可接受的盐、立体异构体或前药，其中B、Z、RA、Rb、Rc、R1、L、L1和E如本文所定义。还提供了与制备和使用此类化合物相关的方法，包括含有这些化合物的药物组合物以及用于调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 1-(6-(3-HYDROXYNAPHTALEN-1-YL)QUINAZOLIN-2-YL)AZÉTIDIN-1-YL)PROP-2-EN-1-ONE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS G12C POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140514A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (Formula (I)) or a pharmaceutically acceptable salt, stereoisomer thereof, wherein G, Y, R, R1, R2a, R2b, R2c, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are quinazoline and quinazolinone derivatives and in particular 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds.

  提供具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：（化学式（I））或其药学上可接受的盐、立体异构体，其中G、Y、R、R1、R2a、R2b、R2c、L、L1和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。优选的化合物是喹唑啉和喹唑啉酮衍生物，特别是1-(6-(3-羟基萘基)喹唑啉-2-基)氮杂环丁烯-1-基)丙-2-烯-1-酮衍生物和类似化合物。
• [EN] FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS N-HÉTÉROCYCLIQUES FUSIONNÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARAXES PHARMA LLC

  公开号：WO2018140598A1

  公开（公告）日：2018-08-02

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, E, L1, Ra. Rb, Rc and ○ are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本发明提供了具有抑制G12C突变KRAS蛋白活性的化合物。该化合物具有以下结构（I）或其药学上可接受的盐、立体异构体或前药，其中A、B、E、L1、RA、Rb、Rc和○的定义如本文所述。本发明还提供了与制备和使用这种化合物相关的方法，包括包含这种化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。